Cerevel Therapeutics Holdings, Inc. (CERE)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 41.99 |
| Open | 41.94 |
| Bid | 41.85 x 800 |
| Ask | 41.92 x 700 |
| Day's Range | 41.87 - 42.06 |
| 52 Week Range | 19.59 - 43.59 |
| Volume | |
| Avg. Volume | 1,415,554 |
| Market Cap | 7.608B |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Yahoo Finance Video
AbbVie acquiring Cerevel Therapeutics in $8.7B deal
AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
© 2024 Yahoo. All rights reserved.